| dc.contributor.author | Watkins, WM | |
| dc.contributor.author | Spencera, HC | |
| dc.contributor.author | Kariuki, DM | |
| dc.contributor.author | Sixsmith, DG | |
| dc.contributor.author | Boriga, DA | |
| dc.contributor.author | Kipingor, T | |
| dc.contributor.author | Koech, DK | |
| dc.date.accessioned | 2013-06-20T09:33:49Z | |
| dc.date.available | 2013-06-20T09:33:49Z | |
| dc.date.issued | 1984 | |
| dc.identifier.citation | The Lancet Volume 323, Issue 8373, 18 February 1984, Pages 357–359 | en |
| dc.identifier.uri | http://www.sciencedirect.com/science/article/pii/S0140673684904100 | |
| dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/36692 | |
| dc.description.abstract | Studies were conducted in Malindi, Kenya, to assess the response of Plasmodium falciparum to chloroquine and amodiaquine in vivo (by an extended 14-day test) and in vitro (with the Rieckmann micro test). In-vivo resistance was demonstrated in 19 of 69 (28%) infections treated with chloroquine, but in only 2 of 60 (3·3%) of those treated with amodiaquine (p<0·001). In-vitro resistance to chloroquine was demonstrated in 15 of 23 (65%) tests. In contrast, 22 of the same 23 isolates were sensitive to amodiaquine in vitro. Effective concentrations by probit analysis for 50% and 99% (EC50 and EC99) inhibition, respectively, were 180·7 and 4319·6 nmol/l for chloroquine and 12·2 and 147·0 nmol/l for amodiaquine. The results suggest that amodiaquine is effective for the treatment of chloroquine-resistant falciparum malaria in Kenya. | en |
| dc.language.iso | en | en |
| dc.publisher | Elsevier | en |
| dc.title | EFFECTIVENESS OF AMODIAQUINE AS TREATMENT FOR CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM INFECTIONS IN KENYA | en |
| dc.type | Article | en |
| local.publisher | Department of pharmacy, University of Nairobi | en |
